InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

MYRIAD GENETICS INC

MYGN Clue Score54
United States Fiscal year ends December CIK 0000899923 Results filed 4 Nov 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

12
Insider
Date
Role
Action
Shares
Price
Amount
Paul Bisaro
14 May 2026
Director
Buy
7,500
$3.69
$27.64K
Samraat S. Raha
9 Mar 2026
President and CEO
Buy
40,000
$5.00
$199.84K
S. Louise Phanstiel
27 Feb 2026
Director
Buy
48,000
$4.66
$223.73K
S. Louise Phanstiel
26 Feb 2026
Director
Buy
50,407
$4.80
$242.10K
S. Louise Phanstiel
25 Feb 2026
Director
Buy
6,100
$4.74
$28.89K
S. Louise Phanstiel
11 Nov 2020
Director
Buy
15,000
$16.62
$249.34K
Walter Phd Gilbert
13 Dec 2019
Director
Buy
5,860
$25.60
$150.00K
John T Henderson
7 Nov 2019
Director
Buy indirect
1,750
$23.46
$41.06K
John T Henderson
7 Nov 2019
Director
Buy
5,250
$23.46
$123.17K
John T Henderson
23 Feb 2017
Director
Buy
400
$18.57
$7.43K
John T Henderson
23 Feb 2017
Director
Buy
3,600
$18.58
$66.89K
John T Henderson
22 Feb 2017
Director
Buy
2,000
$18.81
$37.61K
Show all 135 transactions →

What was left out

Form 4 filings counted 546
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 78
Sales at will 35
Transactions with no price 0
Shares from compensation/vesting 15,234,074
Sales filed before the plan box existed 26
History held since 18 Oct 2006